PBYI
Price
$3.71
Change
+$0.06 (+1.64%)
Updated
Jun 6, 04:34 PM (EDT)
Capitalization
181.18M
55 days until earnings call
VYGR
Price
$3.52
Change
+$0.22 (+6.67%)
Updated
Jun 6, 04:45 PM (EDT)
Capitalization
182.33M
55 days until earnings call
Interact to see
Advertisement

PBYI vs VYGR

Header iconPBYI vs VYGR Comparison
Open Charts PBYI vs VYGRBanner chart's image
Puma Biotechnology
Price$3.71
Change+$0.06 (+1.64%)
Volume$2.3K
Capitalization181.18M
Voyager Therapeutics
Price$3.52
Change+$0.22 (+6.67%)
Volume$1.5K
Capitalization182.33M
PBYI vs VYGR Comparison Chart
Loading...
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYGR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PBYI vs. VYGR commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBYI is a StrongBuy and VYGR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (PBYI: $3.65 vs. VYGR: $3.30)
Brand notoriety: PBYI and VYGR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PBYI: 101% vs. VYGR: 108%
Market capitalization -- PBYI: $181.18M vs. VYGR: $182.33M
PBYI [@Biotechnology] is valued at $181.18M. VYGR’s [@Biotechnology] market capitalization is $182.33M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PBYI’s FA Score shows that 1 FA rating(s) are green whileVYGR’s FA Score has 1 green FA rating(s).

  • PBYI’s FA Score: 1 green, 4 red.
  • VYGR’s FA Score: 1 green, 4 red.
According to our system of comparison, PBYI is a better buy in the long-term than VYGR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PBYI’s TA Score shows that 7 TA indicator(s) are bullish while VYGR’s TA Score has 8 bullish TA indicator(s).

  • PBYI’s TA Score: 7 bullish, 3 bearish.
  • VYGR’s TA Score: 8 bullish, 1 bearish.
According to our system of comparison, VYGR is a better buy in the short-term than PBYI.

Price Growth

PBYI (@Biotechnology) experienced а +7.99% price change this week, while VYGR (@Biotechnology) price change was +16.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.55%. For the same industry, the average monthly price growth was +17.24%, and the average quarterly price growth was +3.49%.

Reported Earning Dates

PBYI is expected to report earnings on Jul 31, 2025.

VYGR is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+11.55% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VYGR($182M) and PBYI($181M) have the same market capitalization . VYGR has higher P/E ratio than PBYI: VYGR (6.00) vs PBYI (4.68). PBYI YTD gains are higher at: 19.672 vs. VYGR (-41.887). PBYI has higher annual earnings (EBITDA): 54.7M vs. VYGR (-97.25M). VYGR has more cash in the bank: 236M vs. PBYI (93.2M). VYGR has less debt than PBYI: VYGR (42M) vs PBYI (61.7M). PBYI has higher revenues than VYGR: PBYI (233M) vs VYGR (67M).
PBYIVYGRPBYI / VYGR
Capitalization181M182M99%
EBITDA54.7M-97.25M-56%
Gain YTD19.672-41.887-47%
P/E Ratio4.686.0078%
Revenue233M67M348%
Total Cash93.2M236M39%
Total Debt61.7M42M147%
FUNDAMENTALS RATINGS
PBYI vs VYGR: Fundamental Ratings
PBYI
VYGR
OUTLOOK RATING
1..100
2776
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
35
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1991
PRICE GROWTH RATING
1..100
4689
P/E GROWTH RATING
1..100
979
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VYGR's Valuation (35) in the Biotechnology industry is in the same range as PBYI (40). This means that VYGR’s stock grew similarly to PBYI’s over the last 12 months.

VYGR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PBYI (100). This means that VYGR’s stock grew similarly to PBYI’s over the last 12 months.

PBYI's SMR Rating (19) in the Biotechnology industry is significantly better than the same rating for VYGR (91). This means that PBYI’s stock grew significantly faster than VYGR’s over the last 12 months.

PBYI's Price Growth Rating (46) in the Biotechnology industry is somewhat better than the same rating for VYGR (89). This means that PBYI’s stock grew somewhat faster than VYGR’s over the last 12 months.

VYGR's P/E Growth Rating (9) in the Biotechnology industry is significantly better than the same rating for PBYI (97). This means that VYGR’s stock grew significantly faster than PBYI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PBYIVYGR
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 19 days ago
78%
Declines
ODDS (%)
Bearish Trend 15 days ago
86%
Bearish Trend 10 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYGR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JLVZX19.84N/A
N/A
JPMorgan Large Cap Value R2
NELIX61.14N/A
N/A
Nuveen Equity Long/Short I
GSPUX40.55N/A
N/A
Goldman Sachs Large Cap Equity R6
DRTHX19.32N/A
N/A
BNY Mellon Sustainable US Eq Fd Z
REPSX38.45N/A
N/A
ProFunds Real Estate UltraSector Svc

PBYI and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBYI has been loosely correlated with AURA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if PBYI jumps, then AURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBYI
1D Price
Change %
PBYI100%
+2.53%
AURA - PBYI
38%
Loosely correlated
-0.57%
COGT - PBYI
38%
Loosely correlated
+6.03%
RGNX - PBYI
37%
Loosely correlated
-17.36%
VYGR - PBYI
35%
Loosely correlated
-0.75%
RARE - PBYI
35%
Loosely correlated
+0.76%
More

VYGR and

Correlation & Price change

A.I.dvisor indicates that over the last year, VYGR has been loosely correlated with TRDA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if VYGR jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VYGR
1D Price
Change %
VYGR100%
-0.75%
TRDA - VYGR
51%
Loosely correlated
+2.14%
KYMR - VYGR
51%
Loosely correlated
+7.68%
RGNX - VYGR
50%
Loosely correlated
-17.36%
XNCR - VYGR
48%
Loosely correlated
+0.22%
IMNM - VYGR
48%
Loosely correlated
+1.16%
More